Investment In New Products: Looking Beyond The R&D Line

Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.

Look Out Cliff edge
• Source: Shutterstock

The Scrip 100 leading five companies, according to R&D spend for 2022, shows many of the usual suspects at the top of the rankings (see Exhibit 1). However, a deeper look at these numbers and taking into account “external” R&D spend such M&A and licensing reveals some upsets and surprise appearances.

Johnson & Johnson and Roche Holding AG’s top billing according to the research spend metric is, perhaps, unsurprising....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from 2024

More from Outlook